Silence Therapeutics PLC (LON:SLN) has been given access to part of a genetic database as it bids to find treatments for rare diseases and ailments.
Genomics England has whole sequencing data on 100,000 genomes.
A genome is an organism’s complete set of DNA, including all of its genes. Each genome contains the information needed to build and maintain that organism.
It is the key to understanding how people differ genetically and therefore how they might respond to different medicines.
Data mining exercise
In the case of Silence, an expert in silencing disease-associated genes, having access to the database will help in its drug development effort.
Under the terms of the deal with Genomics England, Silence will “data mine” a subset of the information to focus on rare diseases and cardio-metabolic illnesses.
It wants to find disease-modifying target genes best suited to its unique technology.
The exercise should also help with “patient stratification” (dividing them into groups and sub-groups) and recruitment as the company develops its RNAi product candidates.
“This key collaboration will help us increase innovation in our target gene choices and will also be attractive to potential partners as we explore a variety of business development opportunities," said Silence chief executive, Dr David Horn Solomon.